CARMAT SAS Announces an Agreement with Edwards Lifesciences to Use the Carpentier-Edwards Biological Heart Valves in CARMAT's Artificial Heart

PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (Paris:ALCAR), the designer and developer of the world's most advanced artificial heart, today announced that it has signed an agreement with Edwards Lifesciences, the global leader in the science of heart valves and hemodynamic monitoring. According to this agreement, CARMAT will be using the Carpentier-Edwards’ biological heart valves in its artificial heart.